Business
Curis Reports Third Quarter 2021 Financial Results and Business Update
Enrolled first patient in Phase 1 Study of CA-4948 combination therapy in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic
About this update from Curis, Inc.
[{"type":"text","content":"Enrolled first patient in Phase 1 Study of CA-4948 combination therapy in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes\n Presented additional preclinical data for CA-4948 demonstrating potential in additional hematologic malignancies at AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics\n Abstract accepted for CI-8993 at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting\n Clinical Data Update Call to be held in January to discuss updated data from ongoing studies, including the Phase 1/2 monotherapy study of CA-4948 in AML/MDS patients with spliceosome or FLT3 mutation\n Management to host conference call today at 4:30 p.m. ET\n\n\nLEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September 30, 2021 and provided business updates.\n\n \n \n \n \n \n \n\n \n\"During the third quarter of 2021, we continued to advance our clinical trials of CA-4948, our first-in-class, small molecule IRAK4 inhibitor in nine distinct patient populations across AML, MDS and B cell cancers, including the recent initiation of our Phase 1 combination study in AML/MDS. At the AACR-NCI-EORTC Conference in October, we shared exciting preclinical data highlighting potential applications for CA-4948 across different hematologic malignancies, including pCNS lymphoma, an aggressive lymphoma with severe unmet need for patients, further highlighting the potential broad applicability of CA-4948,\" said James Dentzer, President and Chief Executive Officer of Curis. \n\"As we look ahead, we plan to provide a clinical data update in January from our ongoing clinical studies, including safety data from our Phase 1 study of CI-8993 and the latest safety and efficacy data from our CA-4948 study in AML/MDS patients with spliceosome or FLT3 mutations.\" \n\"In our ongoing monotherapy AML/MDS study, we expect to achieve our enrollment target of having 10-20 total patients with a spliceosome mutation by year-end. We believe data from these patients may provide for an opportunity to explore discussions with the FDA on a registrational path forward in the first half of 2022,\" concluded Mr. Dentzer....